Drugs / 257049
257049
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials · 1 met primary | ||||||
| Phase 2 | NCT01366534 | Aug 2011 → Feb 2012 | malaria | GlaxoSmithKline | Completed | Met primary |
| Phase 2 | NCT00307021 | Apr → Sep 2006 | Plasmodium falciparum malaria | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT01345240 | Nov 2011 → Jan 2013 | malaria | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01148459 | Jul 2010 → May 2013 | malaria | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 257049 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01148459 ↗ |
| Known as | GSK 257049 | “This study has been designed to support the indication of the candidate vaccine (also referred to as GSK 257049 or RTS,S in this record) against hepatitis B virus infection” NCT01345240 ↗ |
| Known as | RTS,S | “This study has been designed to support the indication of the candidate vaccine (also referred to as GSK 257049 or RTS,S in this record) against hepatitis B virus infection” NCT01345240 ↗ |
| Known as | RTS,S/AS01 | “The RTS,S/AS01 malaria candidate vaccine was reviewed by the European Medicines Agency and received a positive scientific opinion” PMID 27394191 ↗ Jul 2016 |
| Modality | Vaccine | “candidate malaria vaccines” NCT00307021 ↗ |
| Route | Intramuscular | “3-dose intramuscular injection” NCT00307021 ↗ |